| 2025-12-11 |
股东大会：
将于2025-12-31召开股东大会
会议内容 ▼▲
- 1.To elect two Class II director nominees, Douglas Blayney, M.D., and Connie Matsui, to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier resignation or removal, as further described in Proposal No. 1 in the Company’s proxy statement;
2.To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the “Executive Compensation” section of the proxy statement (the “Say-on-Pay Vote”);
3.To transact such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本201.87万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-12.48美元,归母净利润-871.3万美元,同比去年增长-44.06%
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-9.8美元,归母净利润-559.3万美元,同比去年增长-13.77%
|
| 2025-08-07 |
股东大会：
将于2025-08-28召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Articles of Incorporation, as amended (“Articles”), to increase the number of authorized shares of our common stock, par value $0.001 (“Common Stock”), from 8,333,333 to 500,000,000;
2.To approve an amendment of our Articles to increase the number of authorized shares of our preferred stock, par value $0.001 (“Preferred Stock”), from 69,444 to 10,000,000 and to permit the issuance of 10,000,000 shares of Preferred Stock with rights and preferences to be determined by the Board of Directors (the “Board”) from time to time;
3.To ratify the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business as may be properly brought before the Special Meeting or any adjournments or postponements thereof.
|
| 2025-07-07 |
复牌提示：
2025-07-07 10:10:38 停牌，复牌日期 2025-07-07 10:15:38
|
| 2025-06-13 |
详情>>
拆分方案：
每6.0000合并分成1.0000股
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.72美元,归母净利润-237.2万美元,同比去年增长4.47%
|
| 2025-03-03 |
详情>>
业绩披露：
2024年年报每股收益-3.05美元,归母净利润-982.6万美元,同比去年增长-5.78%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.88美元,归母净利润-604.8万美元,同比去年增长2.70%
|
| 2024-11-08 |
股东大会：
将于2024-12-20召开股东大会
会议内容 ▼▲
- 1.To elect two Class I director nominees, Steven Kelly, R. Martin Emanuele, Ph.D., to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier resignation or removal, as further described in Proposal No. 1 in the Company’s proxy statement;
2.To ratify the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To transact such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-1.53美元,归母净利润-491.6万美元,同比去年增长-30.5%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.78美元,归母净利润-248.3万美元,同比去年增长-14.53%
|
| 2024-03-25 |
详情>>
业绩披露：
2023年年报每股收益-3.14美元,归母净利润-928.9万美元,同比去年增长7.87%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.15美元,归母净利润-621.6万美元,同比去年增长7.83%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.32美元,归母净利润-376.7万美元,同比去年增长14.66%
|
| 2023-05-16 |
股东大会：
将于2023-06-30召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors, Steven Kelly, R. Martin Emanuele, Ph.D., Connie Matsui, Douglas Blayney, M.D., Gregory R. Reyes, M.D., Ph.D., Tamara A. (Seymour) Favorito, and Gregory D. Gorgas, for one-, two-, or three-year terms, or until their successors are duly elected and qualified or until their earlier resignation or removal, as further described in Proposal No. 1 in the Company’s proxy statement;
2.To ratify the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To transact such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2022-08-10 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2022-05-26 |
股东大会：
将于2022-06-24召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors, Gregory D. Gorgas, Connie Matsui, Steven Kelly, R. Martin Emanuele, Ph.D., Douglas Blayney, M.D., Gregory R. Reyes, M.D., Ph.D., and Tamara A. Seymour, for a one-year term to expire at the 2023 Annual Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To approve on an advisory (non-binding basis), the compensation of our Named Executive Officer (“Say-on-Pay”);
3.To approve on an advisory (non-binding basis), the frequency at which the Say-on-Pay vote at future annual meetings of stockholders will be held;
4.To approve, for purposes of complying with applicable Nasdaq Listing Rules, the potential issuance and sale of 20% or more of the Company’s common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund LLC pursuant to which Lincoln Park Capital Fund LLC has agreed to purchase from us, from time to time, up to $20,000,000 of our common stock
5.To ratify the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
6.To transact such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-07 |
股东大会：
将于2021-06-18召开股东大会
会议内容 ▼▲
- 1.To elect eight (8) directors, Gregory D. Gorgas, Connie Matsui, Steven Kelly, John W. Beck, R. Martin Emanuele, Ph.D., Douglas Blayney, M.D., Gregory R. Reyes, M.D., Ph.D., and Tamara A. Seymour, for a one-year term to expire at the 2022 Annual Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To ratify the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending August 31, 2021 and for the stub period between September 1, 2021 and December 31, 2021;
3.To transact such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-04-16 |
详情>>
内部人交易：
Gorgas Gregory D.股份增加8500.00股
|
| 2020-11-09 |
股东大会：
将于2020-12-03召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Articles of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock, par value $0.001, (“Common Stock”) from 18,750,000 to 750,000,000;
2.To approve an amendment to the 2018 Equity Incentive Plan (the “2018 Plan”), which would increase the number of shares of Common Stock reserved for issuance under the 2018 Plan by 2,000,000 shares and extend the term of the 2018 Plan until October 2030;
3.To authorize one or more adjournments of the Special Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 1 and/or Proposal 2 described above.
|
| 2020-05-08 |
股东大会：
将于2020-06-19召开股东大会
会议内容 ▼▲
- 1.To elect six directors, Gregory D. Gorgas, Connie Matsui, Steven Kelly, John W. Beck, R. Martin Emanuele, Ph.D., and Douglas Blayney, M.D., for a one-year term to expire at the 2021 Annual Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier resignation or removal;
2.To amend the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 425,000 shares
3.To amend the 2018 Plan to add a provision that provides for automatic annual increases to the number of shares reserved for issuance under the 2018 Plan;
4.To ratify the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending August 31, 2020;
5.To transact such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|